Waters Corporation (WAT) - 2025 Annual Report (10-K) Summary
Business Context and Reporting Period
This summary covers the fiscal year ended December 31, 2025. Waters Corporation is a global leader in analytical instruments and software, primarily serving life sciences, materials, and food sciences. The company operates through two primary segments: Waters (LC, MS, and consumables) and TA Instruments (thermal analysis, rheometry, and calorimetry).
Material Subsequent Event: On February 9, 2026, Waters completed the acquisition of the Biosciences and Diagnostic Solutions (BDS) businesses of Becton, Dickinson and Company (BD) for a total purchase price of $16.8 billion (including assumed debt). This transaction, structured as a Reverse Morris Trust, significantly expands Waters' capabilities in diagnostics and life sciences. The 2025 financial results presented herein do not include the BDS Business.
Key Financial Metrics (Fiscal Year 2025)
| Metric | 2025 | 2024 | Change |
|---|---|---|---|
| Total Net Sales | $3,165.3 million | $2,958.4 million | +7% |
| Operating Income | $802.6 million | $826.4 million | -3% |
| Operating Margin | 25.4% | 27.9% | -250 bps |
| Net Income | $642.6 million | $637.8 million | +1% |
| Diluted EPS | $10.76 | $10.71 | Flat |
| Operating Cash Flow | $652.6 million | $762.1 million | -14% |
| Total Debt (Outstanding) | $1.4 billion | $1.6 billion | -12% |
| Cash & Equivalents | $587.8 million | $325.4 million | +81% |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 7% driven by strong demand for Waters Division products, particularly in China (+10%) and Europe (+10%). Chemistry consumables sales grew 12% due to uptake in columns and testing kits.
- Operating Income Decline: Despite revenue growth, operating income decreased 3% due to higher sales volume costs, merit increases, and approximately $82 million in transaction, integration, and internal costs related to the BDS acquisition. Additionally, $20 million in expenses were incurred for a new ERP system implementation.
- China Recovery: Sales in China rebounded with a 10% increase in 2025, reversing a 10% decline in 2024 caused by regulatory tightening and macroeconomic conditions.
- Acquisitions: In May 2025, Waters acquired Halo Labs for $35 million to enhance particle analysis capabilities. The larger BD acquisition closed in early 2026.
Guidance, Outlook, and Risks
Outlook & Strategy: Management expects foreign currency translation to be neutral to gross profit in 2026. The company plans to refinance the $3.5 billion tranche of debt assumed from the BD acquisition in Q1 2026 with long-term bond financing. The company has a remaining share repurchase authorization of $1.0 billion.
Key Risks & Contingencies:
- Integration Risk: Failure to successfully integrate the BDS Business within the expected timeline could adversely affect future results and prevent realization of anticipated synergies ($200M cost synergies in 3 years; $290M revenue synergies in 5 years).
- Debt Load: The BDS acquisition added $4.0 billion in indebtedness (assumed in Feb 2026), significantly increasing leverage and borrowing costs.
- Macroeconomic & Geopolitical: Risks include trade tariffs (U.S. Supreme Court invalidated certain tariffs in Feb 2026, creating uncertainty), foreign currency fluctuations, and economic conditions in China.
- ERP Implementation: Transitioning to a new worldwide ERP system involves significant costs and operational risks, with total anticipated spending of $130 million.
Investor Verification Checklist
- BDS Integration Progress: Monitor Q1 2026 earnings for updates on the integration timeline and realization of cost/revenue synergies.
- Debt Refinancing: Verify the terms and success of the planned refinancing of the $3.5 billion BD debt tranche in Q1 2026.
- China Sales Sustainability: Assess whether the 10% sales growth in China is sustainable given ongoing geopolitical tensions and regulatory environments.
- ERP Costs: Track the remaining $78 million in anticipated ERP implementation costs and potential operational disruptions.
- Segment Reporting Changes: Note that the company will reorganize into four new segments (Analytical Sciences, Biosciences, Advanced Diagnostics, Materials Sciences) for future reporting periods post-BDS acquisition.